Compare UXIN & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UXIN | VALN |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | China | France |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 756.6M | 855.8M |
| IPO Year | 2018 | 2021 |
| Metric | UXIN | VALN |
|---|---|---|
| Price | $3.66 | $9.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.75 |
| AVG Volume (30 Days) | ★ 318.4K | 13.2K |
| Earning Date | 03-13-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | ★ $395,809,853.00 | $211,089,992.00 |
| Revenue This Year | $237.18 | $3.64 |
| Revenue Next Year | $145.46 | $12.23 |
| P/E Ratio | $4.16 | ★ N/A |
| Revenue Growth | ★ 73.08 | 13.48 |
| 52 Week Low | $2.45 | $5.43 |
| 52 Week High | $5.41 | $12.25 |
| Indicator | UXIN | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 57.65 | 56.14 |
| Support Level | $3.03 | $9.20 |
| Resistance Level | $3.75 | $9.88 |
| Average True Range (ATR) | 0.20 | 0.29 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 92.47 | 66.44 |
Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates used car e-commerce platforms through its mobile applications and websites. It facilitates used car transaction services and financing solutions offered by third-party financing partners to buyers for their used car purchases. The company generates revenue through sales of the commission of salvage car sales, and interest income from the financial lease. The Group generates its revenues in China, and assets of the company are also located in China Area.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.